Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease

Phase 2 Completed NCT02947893

Summary

The investigators hypothesize that Nilotinib will be safe in individuals with mild to moderate AD. Specifically, investigators hypothesize that low daily oral doses of Nilotinib will lead to CSF penetration, CNS Abl inhibition, and stabilization of CSF total Tau and p-Tau231/181 and Abeta42/40 levels. The investigators hypothesize that Nilotinib will decrease brain load of amyloid using amyloid positron emission tomography (PET). The investigators also predict that Nilotinib will reduce CSF markers of cell death, including neuron specific enolase (NSE) and S100B.

Safety Will be Measured by Number of Participants Experiencing the Occurrence of Adverse Events and/or Abnormal Laboratory Values

12 months · events

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• Brain Energy for Amyloid Transformation in Alzheimer's Disease Study — Wake Forest University Health Sciences
• Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss — Eli Lilly and Company
• Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia — Icahn School of Medicine at Mount Sinai
• Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges — Brigham and Women's Hospital
• Technology and Family Thriving Study — University of California, Santa Barbara
• Community-based Brain Health Program to Address Dementia Risk — Posit Science Corporation

All trials